Quarterly ResultAug 12, 2026, 07:38 AM
Sutro Biopharma Q2 2026 Net Loss $38.5M; Revenue $9.8M
AI Summary
Sutro Biopharma reported a net loss of $38.5 million for Q2 2026, with revenue of $9.8 million. For the six months ended June 30, 2026, the net loss was $77.0 million on $24.4 million in revenue. The company completed a public offering in February 2026, raising $110.0 million, and had $164.3 million in unrestricted cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations for at least 12 months. These results follow significant restructuring plans in 2025 and a 1-for-10 reverse stock split.
Key Highlights
- Q2 2026 net loss was $38.5 million, compared to $11.5 million in Q2 2025.
- Q2 2026 revenue was $9.8 million, down from $63.7 million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $77.0 million, compared to $87.5 million in the prior year.
- Revenue for the six months ended June 30, 2026, was $24.4 million, down from $81.1 million in the prior year.
- Unrestricted cash, cash equivalents, and marketable securities totaled $164.3 million as of June 30, 2026.
- Completed a public offering in February 2026, raising approximately $110.0 million in gross proceeds.
- Implemented restructuring plans in March and September 2025, reducing workforce by approximately two-thirds.
- A 1-for-10 reverse stock split was implemented on December 2, 2025.
Price Impact
More from STRO